MedTrace Logo

Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis

NCT05795491 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-05-02

No results posted yet for this study

Summary

With the knowledge that VVC is an infectious disease of the genitourinary tract that is common in women of reproductive age, and because of the shortage of non-drug therapies for this condition, this study will aim to evaluate the effect of ultraviolet A/blue LED with a wavelength of 401 ± 5 nm in patients with a clinical manifestation of candidiasis and its ability to prevent recurrence.

Conditions

  • Recurrent Vulvovaginal Candidiasis

Interventions

DEVICE

Blue Light Emitting Diode Therapy

Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.

DRUG

Azole Antifungal

Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Soheir El-kosery, PHD · Professor of physical Therapy, Faculty of Physical therapy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2023-05-01
Completion
2023-06-01
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795491 on ClinicalTrials.gov